Loading clinical trials...

TERMINATEDPHASE1

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men

NCT02676310•Allergan

View on ClinicalTrials.gov

Summary

This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).

Eligibility

Age

18 - 49 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year

Exclusion Criteria

•History of Paget's disease, osteoporosis, or bone malignancy
•History of bone fracture within the previous 12 months, except for metatarsal, metacarpal, or skull fractures
•Patient is currently undergoing radiation therapy or anticipates undergoing radiation therapy at any time during the study
•Drug or alcohol abuse within 12 months
•HIV positive
•Received hair transplants or had scalp reductions
•Use of hair weaves, hair extensions or wigs within 3 months
•Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks

Locations (3)

DermResearch, LLC

Austin, Texas, United States

J&S Studies Inc.

College Station, Texas, United States

E&R Research Foundation

Lynchburg, Virginia, United States

Key Dates

Start Date

March 1, 2016

Primary Completion Date

January 1, 2017

Completion Date

March 1, 2017

Last Updated

March 17, 2017

Enrollment

ACTUAL participants

Conditions

AlopeciaAlopecia, AndrogeneticBaldness

Interventions

Bimatoprost

DRUG

Androgenic Alopecia TH07 Clinical Trial

NCT07435012

Androgenic Alopecia

View study

RECRUITINGPHASE1/PHASE2

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196

Alopecia Areata (AA)

View study

RECRUITINGNA

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

NCT07107841

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Inclusion Criteria

Exclusion Criteria

Androgenic Alopecia TH07 Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata